CoChat

Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50

Open access
Bohula, Erin A., Aylward, Philip E., Bonaca, Marc P., Corbalan, Ramon L., Kiss, Robert G., Murphy, Sabina A., Scirica, Benjamin M., White, Harvey, Braunwald, Eugene, Morrow, David A. · 2015 · Circulation
Cited by 38

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background—: Vorapaxar antagonizes protease-activated receptor 1, the primary receptor for thrombin on human platelets, and reduces recurrent thrombotic events in stable patients with a previous myocardial infarction (MI). We wished to determine whether the efficacy and safety of antiplatelet therapy with vorapaxar was modified by concurrent thienopyridine use. Methods and Results—: The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with previous atherothrombosis. This prespecified analysis included 16 897 patients who qualified with a MI in the preceding 2 weeks to 12 months and was restricted to patients without a history of stroke or transient ischemic attack given its contraindication in that population. Randomization was stratified on the basis of planned thienopyridine use. Thienopyridine was planned at randomization in 12 410 (73%). Vorapaxar significantly reduced the composite of cardiovascular death, MI, and stroke in comparison with placebo regardless of planned thienopyridine therapy (planned thienopyridine, hazard ratio, 0.80, 0.70–0.91, P <0.001; no planned thienopyridine, hazard ratio, 0.75; 0.60–0.94, P =0.011; P -interaction=0.67). Findings were similar when patients were stratified by actual thienopyridine use at baseline ( P -interaction=0.82) and through 18 months ( P -interaction=0.44). Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) moderate or severe bleeding risk was increased with vorapaxar and was not significantly altered by planned thienopyridine (planned, hazard ratio, 1.50; 1.18–1.89, P <0.001; no planned, hazard ratio, 1.90, 1.17–3.07, P =0.009; P -interaction=0.37) or actual thienopyridine use ( P -interaction=0.24). Conclusions—: Vorapaxar reduced cardiovascular death, MI, or stroke in stable patients with a history of previous MI, whether treated concomitantly with a thienopyridine or not. The relative risk of moderate or severe bleeding was similarly increased irrespective of thienopyridine use. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00526474.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.114.015042

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Long-term use of ticagrelor in patients with prior myocardial infarction

    Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999 · cited 2×

    “Additionally, in the PEGASUS-TIMI 54 Trial, extended P2Y12 inhibition with the addition of ticagrelor to aspirin reduced major cardiovascular events in patients with an MI within 1-3 years of enrollment.(10) In both of these trials, the atherothrombotic benefits came at the cost of increased bleeding.”
    BackgroundMethodSelf-citation
  • Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

    Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928 · cited 2×

    “The addition of more potent antiplatelet therapy to aspirin via P2Y12 adenosine diphosphate (ADP) receptor inhibition resulted in a reduction in recurrent cardiovascular events when used for at least one year following an acute coronary syndrome (ACS) or for at least 30 months following percutaneous coronary intervent…”
    MethodSelf-citation

Cited by

See all 38

Metadata

Authors
Bohula, E. A., Aylward, P. E., Bonaca, M. P., Corbalan, R. L., Kiss, R. G., Murphy, S. A., Scirica, B. M., White, H., Braunwald, E., & Morrow, D. A.
Venue
Circulation
Published
2015-11-17
Volume
132
Issue
20
Pages
1871-1879
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2174434727
Cited by
38
References
2
FWCI
4.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.